Biography:
Dr. Robert J. Chilton, MD, FAHA, FACC, is a renowned Professor of Medicine with a distinguished career in cardiovascular disease, heart failure, and diabetes, particularly type 2 diabetes (T2DM). He trained at the University of Oklahoma and Wilford Hall USAF, later leading key studies on coronary artery disease (CAD) and heart failure. Dr. Chilton has contributed over 100 publications and participated in pivotal trials, such as COURAGE, ISCHEMIA, and BARI-2D, shaping global CAD and diabetes treatment. He is also associate editor for CCI, Journal of Diabetes and CV metabolism. Moreover, in 2024 Best Teacher Award recipient, his research focuses on SGLT2 inhibitors for T2DM and heart failure, as well as proteomics in acute myocardial infarction.
Title : Revolutionizing CKD care: How finerenone transforms outcomes in heart and kidney health - Insights from fidelio-DKD
Title : Advancements in atherothrombotic disease treatment: Unveiling the potential of SGLT2/1 Agents